Main scientific milestone marks SINTX’s entry into the foot and ankle reconstruction market and advances commercialization of its silicon nitride biomaterial platform
SALT LAKE CITY, Utah, March 19, 2026 (GLOBE NEWSWIRE) — SINTX Applied sciences, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a pacesetter in superior ceramic biomaterials and silicon nitride medical gadget innovation, in the present day introduced the profitable completion of the first-in-human surgical process using its FDA-cleared SINAPTIC® Foot & Ankle Osteotomy Wedge System, marking a significant scientific and business milestone within the Firm’s growth into the worldwide orthopedic gadget market.
The process represents SINTX’s entry into the foot and ankle reconstruction section, a major and rising class inside the multi-billion-dollar orthopedic implant market, and underscores the Firm’s technique to commercialize its proprietary silicon nitride biomaterial platform throughout a number of surgical functions.
The SINAPTIC Foot & Ankle Osteotomy Wedge System obtained U.S. FDA 510(okay) clearance in October 2025 and integrates surgeon-informed design with SINTX’s silicon nitride know-how, which has demonstrated in printed information its:
osteoconductive and pro-osteogenic propertiesbacteriostatic floor characteristicshydrophilicityradiographic compatibility with X-ray, CT, and MRI imaging
More Read
“This first-in-human procedure is a defining milestone for SINTX and a critical step in our commercialization strategy,” mentioned Eric Okay. Olson, Chief Government Officer of SINTX Applied sciences. “We are now translating years of materials science innovation into real-world surgical applications. Entry into the foot and ankle market expands our addressable opportunity and positions silicon nitride as a differentiated biomaterial platform capable of driving future revenue growth and broader surgeon adoption.”
The primary process was carried out on March 13, 2026 by Dr. Scott Carrington, DPM, FACFAS, at Emplify Well being in La Crosse, Wisconsin, using the SINAPTIC wedge in a reconstructive foot and ankle process.
“The implant performed exceptionally well and provided the structural integrity and imaging clarity that are critical in these cases,” mentioned Dr. Carrington. “Silicon nitride is a compelling material because it combines mechanical performance with biologic interaction, which are key considerations in reconstructive surgery.”
More Read
In contrast to conventional steel and plastic implants, silicon nitride has been studied for its capacity to:
assist bone integrationreduce bacterial adhesion on the implant surfaceenable improved post-operative imaging
These traits could enable surgeons to raised assess implant positioning and therapeutic development, doubtlessly enhancing scientific decision-making throughout restoration.
“For surgeons, this represents access to a next-generation biomaterial,” mentioned Lisa Marie Del Re, Chief Industrial Officer of SINTX Applied sciences. “For patients, it reflects the potential benefits of a material engineered to support bone healing and reduce complications. From a commercial standpoint, this milestone is an important step toward broader market adoption of the SINAPTIC platform.”
The profitable completion of this primary process helps SINTX’s broader technique to increase past backbone functions and set up silicon nitride as a platform know-how throughout orthopedic and medical gadget markets, together with rising functions equivalent to SiNERGY™ SiN/PEEK composites and antipathogenic biomaterials.
SINTX expects the SINAPTIC system to assist a U.S. business launch and contribute to the Firm’s long-term progress technique.
More Read
For extra data on SINTX Applied sciences or its biomaterial platforms, go to www.sintx.com.
About SINTX
Headquartered in Salt Lake Metropolis, Utah, SINTX Applied sciences, Inc. (NASDAQ: SINT) is a sophisticated ceramics firm that develops, manufactures, and commercializes silicon nitride biomaterials, composites, gadgets, and associated applied sciences for medical and different high-value functions. With hundreds of medical gadgets implanted since 2008 and almost 20 years of peer-reviewed analysis, SINTX has established itself as a pacesetter in high-performance biomaterials that improve scientific outcomes and affected person security. Supported by a powerful patent portfolio, U.S.-based manufacturing, and strategic business partnerships, the corporate continues to increase its know-how platform via innovation and market diversification, together with the not too long ago FDA-cleared SINAPTIC® Foot & Ankle Implant System for reconstructive surgical procedure.
Ahead-Wanting Statements
This press launch incorporates “forward-looking statements” inside the that means of the Personal Securities Litigation Reform Act of 1995, together with, with out limitation, statements relating to: the scientific and business significance of the preliminary use of the SINAPTIC® Foot & Ankle Osteotomy Wedge System; the Firm’s technique to increase its silicon nitride biomaterial platform throughout orthopedic and different medical functions; the anticipated timing and success of commercialization efforts; anticipated market adoption, surgeon acceptance, and scientific utilization; and the potential of silicon nitride-based applied sciences, together with SiNERGY™ SiN/PEEK composites and antipathogenic supplies. Ahead-looking statements are based mostly on present expectations and assumptions and are topic to important dangers and uncertainties. Precise outcomes could differ materially from these expressed or implied by such statements as a result of quite a lot of elements, together with, however not restricted to: the Firm’s capacity to efficiently commercialize newly cleared merchandise; variability in surgeon adoption and scientific expertise; affected person outcomes in broader use; regulatory necessities and limitations on promotional claims; the Firm’s capacity to scale manufacturing and keep high quality techniques; reliance on third-party companions and suppliers; aggressive merchandise and applied sciences; pricing and reimbursement dynamics; and normal financial and capital market circumstances.
Statements relating to materials properties or organic traits of silicon nitride are based mostly on laboratory testing and printed analysis and will not be indicative of scientific efficiency in all circumstances. References to antipathogenic or infection-related attributes mirror ongoing analysis and don’t suggest FDA clearance, authorised indications, or scientific efficacy for any particular product or use. Further dangers and uncertainties are described within the Firm’s filings with the Securities and Alternate Fee, together with its most up-to-date Annual Report on Kind 10-Okay and Quarterly Experiences on Kind 10-Q. Ahead-looking statements communicate solely as of the date of this launch, and the Firm undertakes no obligation to replace them besides as required by legislation.
SINTX Contacts:
